News

Era7 Bioinformatics announces today the successful closing of its crowdfunding campaign. The 100 percent of the funding goal has been covered using Capital Cell Life Sciences equity crowdfunding platform:

First of all, Era7 wishes to thank all the investors and especially CRB Inverbio, the lead investor of the round.

Today, we have a special milestone in our company which will drive us to expand our presence in the USA market. Our great team has been doing a lot of high quality R&D activities during the last years. At this stage, what we want is to increase sales based on all this value. This Expansion Plan will be funded with this campaign and allow us to get more customers for our new services of Microbiome analysis, Bacterial Genomics and Immunogenomics.

Declared Era7’s CEO Dr. Eduardo Pareja.

In addition, it has been a real pleasure to see how our collaborators, clients and providers have trusted on us investing in our company. We are very proud of it, since the people that better knows Era7 Bioinformatics have invested in the company.

Added Dr. Eduardo Pareja.

The crowdfunding campaign, which was done with the goal of raising 600000 euros for a 20% of the company (a pre-money valuation of 2.4 millions of euros), has been totally covered by more than 50 investors. It is intended to fund an special effort in Business Development in the USA market where Era7 is doing business through its subsidiary Era7 Bioinformatics Inc. registered at Cambridge MA.